The FDA has accepted for Priority Review the NDA for SL1009 to treat pyruvate dehydrogenase complex deficiency.

DCA is a targeted therapy that inhibits Pyruvate Dehydrogenase Kinase (PDK) to stimulate residual Pyruvate Dehydrogenase Complex (PDC) activity and increase energy (ATP) production by mitochondria.

Just before she turned one, Harlow was diagnosed with Pyruvate Dehydrogenase Complex Deficiency, commonly called PDCD.

Indications: Pyruvate dehydrogenase complex deficiency, typically associated with post-prandial lactic acidemia with a normal lactate/pyruvate ratio, can be assayed in freshly isolated blood ...

As a result, they play an extremely important role in metabolism. Individual enzymes frequently form a complex with many subunits, as in the case of the pyruvate dehydrogenase complex.

The pyruvate dehydrogenase complex consists of many different enzymes (marked in different colours).

Calcium ions regulate the citric acid cycle by activating pyruvate dehydrogenase, the first component of the pyruvate dehydrogenase complex reaction that forms acetyl-CoA.

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

DCA is a targeted therapy that inhibits Pyruvate Dehydrogenase Kinase (PDK) to stimulate residual Pyruvate Dehydrogenase Complex (PDC) activity and increase energy (ATP) production by mitochondria.